Mebeverine Hydrochloride Morningside Healthcare (Mebeverine Hydrochloride)

Mebeverine Hydrochloride is used to manage gastrointestinal spasm and related functional bowel conditions.

• Irritable bowel syndrome (IBS): reduces abdominal pain, cramping, bloating and irregular bowel movements, improving overall quality of life.
• Functional bowel disorders: alleviates intestinal spasms, decreases discomfort and normalizes bowel habits in conditions such as functional dyspepsia.
• Abdominal cramping due to intestinal spasm: provides rapid symptomatic relief of painful muscle contractions associated with various gastrointestinal disturbances.

• Mebeverine Hydrochloride acts as a direct smooth‑muscle relaxant. It inhibits calcium influx into intestinal smooth‑muscle cells, thereby reducing contractility and spasm. The drug may also possess anticholinergic activity, contributing to decreased motility. By targeting the musculotropic pathways of the gastrointestinal tract, it lessens the intensity of spasmodic episodes without markedly affecting normal peristalsis. The effect is localized to the gut, minimizing systemic anticholinergic side effects.

Mebeverine Hydrochloride may be associated with a range of adverse reactions, which are categorised by frequency and severity.

Common Side Effects

• Nausea: mild stomach upset reported in some patients.
• Dry mouth: reduced salivation leading to throat discomfort.
• Headache: transient head pain without neurological signs.
• Dizziness: light‑headed sensation, especially on standing.

Serious or Rare Side Effects

• Allergic reactions: rash, itching, swelling or anaphylaxis.
• Severe hypotension: marked drop in blood pressure causing faintness.
• Hepatic dysfunction: elevated liver enzymes or jaundice.

When prescribing Mebeverine Hydrochloride, clinicians should consider several precautionary measures to ensure safe use.

• Pregnancy: safety not established; use only if potential benefit justifies the risk.
• Breastfeeding: unknown excretion; weigh benefits against possible infant exposure.
• Elderly patients: monitor for increased sensitivity to anticholinergic effects.
• Renal or hepatic impairment: dose adjustment may be required; assess organ function.
• Concomitant medications: review for possible interactions before initiating therapy.
• Store at ambient temperature: keep in original packaging, protect from moisture and light.

Mebeverine Hydrochloride can interact with other medicines; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid)

• Potent CYP3A4 inhibitors: may increase mebeverine plasma concentrations, raising risk of adverse effects.
• Anticholinergic agents: additive anticholinergic activity can exacerbate dry mouth and constipation.
• Other smooth‑muscle relaxants: combined effect may cause excessive gastrointestinal hypomotility.

Moderate Interactions (Monitor Closely)

• Tricyclic antidepressants: potential increase in anticholinergic side effects.
• Antihistamines: may enhance dry mouth and dizziness.
• Alcohol: can intensify dizziness and hypotensive effects.